TY - JOUR
T1 - Severe Anaphylactic Reactions to Home Doses of Oral Immunotherapy for Food Allergy
AU - Nachshon, Liat
AU - Schwartz, Naama
AU - Levy, Michael B.
AU - Goldberg, Michael
AU - Epstein-Rigbi, Naama
AU - Katz, Yitzhak
AU - Elizur, Arnon
N1 - Publisher Copyright:
© 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023/8
Y1 - 2023/8
N2 - Background: Severe anaphylactic reactions to home doses may occur during food allergy oral immunotherapy (OIT). Objective: To study the rate and risk factors for such reactions. Methods: We studied all patients aged greater than 3.5 years who completed OIT in a single center between April 2010 and January 2020. All home epinephrine-treated reactions (HETRs) were identified. High-grade HETRs (HG-HETRs) were defined as HETRs involving respiratory (SpO2 of 94% or less), cardiovascular (low blood pressure), or central nervous system impairment (loss of consciousness). We investigated the rate and risk factors for HG-HETRs. Results: A total of 1,637 OIT treatments were studied: milk (880), peanut (346), tree nuts (221), sesame (115), and egg (75). Of 390 identified HETRs, 30 HG-HETRs occurred during 27 treatments (1.65% of all treatments). Nearly all (26 of 30) were during milk OIT in patients with house dust mite (HDM) sensitization and asthma (26 of 30 each). Of the 30 patients with HG-HETRs, 21 recovered with one or two epinephrine treatments, but nine (0.55% of all treatments) did not respond to a second dose of epinephrine and were deemed to have refractory anaphylaxis. Three patients required intensive care unit admission and three received epinephrine drip, but none required ventilatory support. Risk factors for HG-HETRs included milk OIT (P = .031), asthma (P = .02) and HDM sensitization (P = .02). No specific triggers for HG-HETR were identified. Of patients with HG-HETRs, 25.9% were fully desensitized, including the four non–milk treated patients; 22.2% were partially desensitized; and 51.9% failed. Conclusions: High-grade HETRs are uncommon, particularly refractory anaphylactic reactions to home OIT doses. Although milk OIT, asthma, and HDM sensitization are the main risk factors for such reactions, identification of patients who are at risk is challenging.
AB - Background: Severe anaphylactic reactions to home doses may occur during food allergy oral immunotherapy (OIT). Objective: To study the rate and risk factors for such reactions. Methods: We studied all patients aged greater than 3.5 years who completed OIT in a single center between April 2010 and January 2020. All home epinephrine-treated reactions (HETRs) were identified. High-grade HETRs (HG-HETRs) were defined as HETRs involving respiratory (SpO2 of 94% or less), cardiovascular (low blood pressure), or central nervous system impairment (loss of consciousness). We investigated the rate and risk factors for HG-HETRs. Results: A total of 1,637 OIT treatments were studied: milk (880), peanut (346), tree nuts (221), sesame (115), and egg (75). Of 390 identified HETRs, 30 HG-HETRs occurred during 27 treatments (1.65% of all treatments). Nearly all (26 of 30) were during milk OIT in patients with house dust mite (HDM) sensitization and asthma (26 of 30 each). Of the 30 patients with HG-HETRs, 21 recovered with one or two epinephrine treatments, but nine (0.55% of all treatments) did not respond to a second dose of epinephrine and were deemed to have refractory anaphylaxis. Three patients required intensive care unit admission and three received epinephrine drip, but none required ventilatory support. Risk factors for HG-HETRs included milk OIT (P = .031), asthma (P = .02) and HDM sensitization (P = .02). No specific triggers for HG-HETR were identified. Of patients with HG-HETRs, 25.9% were fully desensitized, including the four non–milk treated patients; 22.2% were partially desensitized; and 51.9% failed. Conclusions: High-grade HETRs are uncommon, particularly refractory anaphylactic reactions to home OIT doses. Although milk OIT, asthma, and HDM sensitization are the main risk factors for such reactions, identification of patients who are at risk is challenging.
KW - Adverse reactions
KW - Anaphylaxis
KW - Epinephrine
KW - Oral immunotherapy
KW - Vital sign
UR - http://www.scopus.com/inward/record.url?scp=85152678806&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2023.03.005
DO - 10.1016/j.jaip.2023.03.005
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36925102
AN - SCOPUS:85152678806
SN - 2213-2198
VL - 11
SP - 2524-2533.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 8
ER -